Filtros de búsqueda

Lista de obras de

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

scientific article published on 09 May 2019

A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease

artículo científico publicado en 2015

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

artículo científico publicado en 2018

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

artículo científico publicado en 2013

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2007

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome

artículo científico publicado en 2011

A randomized, phase 2 study of R-CHOP plus enzastaurin vs R-CHOP in patients with intermediate- or high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2015

ABVD plus rituximab ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study

artículo científico publicado en 2018

ASHAP: a regimen for cytoreduction of refractory or recurrent Hodgkin's disease

artículo científico publicado en 1999

AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

artículo científico publicado en 2015

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

artículo científico publicado en 2019

Analysis of in-field control and late toxicity for adults with early-stage Hodgkin's disease treated with chemotherapy followed by radiotherapy.

artículo científico publicado en 2003

Anaplastic large cell lymphoma associated with breast implants: a report of 13 cases

artículo científico publicado en 2012

Association of HLA phenotype and response to interferon-alpha in patients with chronic myelogenous leukemia

scientific article published on 01 April 1998

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

artículo científico publicado en 2020

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.

artículo científico publicado en 2011

Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study

artículo científico publicado en 2008

Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma.

artículo científico publicado en 2015

Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy

artículo científico publicado en 2010

Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification

artículo científico publicado en 2009

Body mass index and outcomes in patients receiving chemotherapy for intermediate-grade B-cell non-Hodgkin lymphoma ⬇️

artículo científico publicado el 1 de septiembre de 2010

Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma

artículo científico publicado en 2018

Bortezomib-resistant nuclear factor κB expression in stem-like cells in mantle cell lymphoma

artículo científico publicado en 2011

Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients.

artículo científico publicado en 2013

Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma

artículo científico publicado en 2020

Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?

artículo científico publicado en 2011

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

artículo científico publicado en 2012

Can we cure refractory Hodgkin's lymphoma with transplantation?

artículo científico publicado en 2020

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

artículo científico publicado en 2015

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

artículo científico publicado en 2020

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

artículo científico publicado en 2017

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

artículo científico publicado en 2015

Classical Hodgkin lymphoma arising in the setting of iatrogenic immunodeficiency: a clinicopathologic study of 10 cases

artículo científico publicado en 2013

Classical Hodgkin's Lymphoma Associated With Langerhans Cell Histiocytosis: Multiagent Chemotherapy Resulted in Histologic Resolution of Both the Classical Hodgkin's Lymphoma and Langerhans Cell Proliferation Components ⬇️

artículo científico publicado el 1 de febrero de 2011

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

scientific article published on 13 March 2012

Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma

artículo científico publicado en 2013

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

artículo científico publicado en 2017

Comparison of referring and tertiary cancer center physician's diagnoses in patients with leukemia

artículo científico publicado en 1998

Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed disease

artículo científico publicado en 2015

Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy.

artículo científico publicado en 2017

Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas

artículo científico publicado en 2005

Could treatment with R-HCVAD/R-MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al.

artículo científico publicado en 2013

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,

artículo científico publicado en 2015

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

artículo científico publicado en 2019

Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach

artículo científico publicado en 2015

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring

artículo científico publicado en 2016

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions.

artículo científico publicado en 2017

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

artículo científico publicado en 2016

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

artículo científico publicado en 2016

Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin B cell lymphoma

artículo científico publicado en 2006

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

artículo científico publicado en 2014

Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review

artículo científico publicado en 2015

Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome

artículo científico publicado en 2015

Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?

artículo científico publicado en 2017

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

scientific article published on 02 April 2020

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

artículo científico publicado en 2008

Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases.

artículo científico publicado en 1997

Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue

scientific article published on 03 January 2019

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2017

Establishment and characterization by gene expression profiling of a new diffuse large B-cell lymphoma cell line, EJ-1, carrying t(14;18) and t(8;14) translocations

artículo científico publicado en 2003

Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma

artículo científico publicado en 2006

Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma

artículo científico publicado en 2007

Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.

artículo científico publicado en 2012

Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era

artículo científico publicado en 2016

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 01 May 2019

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

artículo científico publicado en 2008

Follicular dendritic cell sarcoma: a report of 14 cases and a review of the literature

artículo científico publicado en 2007

Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features.

artículo científico publicado en 1999

Follicular large cell lymphoma: long-term follow-up of 62 patients treated between 1973-1981

artículo científico publicado en 2000

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

artículo científico publicado en 2018

Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma

artículo científico publicado en 2003

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

scientific article published on 06 March 2019

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

scientific article published on 01 March 2020

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

artículo científico publicado en 2011

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

scientific article published on 30 July 2020

Hematopoietic stem cell transplantation for Hodgkin's disease

artículo científico publicado en 2011

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

artículo científico publicado en 2005

High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma

artículo científico publicado en 1998

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

artículo científico publicado en 2017

High-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma

artículo científico publicado en 2008

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

artículo científico publicado en 2018

Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.

artículo científico publicado en 2006

Hodgkin's disease variant of Richter's syndrome: experience at a single institution

Artículo científico publicado en 1996

Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results.

artículo científico publicado en 2009

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

artículo científico publicado en 2015

Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement

artículo científico publicado en 2020

Ifosfamide, carboplatin, etoposide with or without bortezomib in patients with relapsed/refractory Hodgkin lymphoma: results of a randomized phase II trial

artículo científico publicado en 2015

Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission

scientific article published on 20 February 2020

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

scientific article published on 11 February 2019

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

artículo científico publicado en 2018

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

artículo científico publicado en 2020

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

scientific article published on 01 April 2006

Incidence and risk factors of venous thromboembolic events in lymphoma.

artículo científico publicado en 2010

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

artículo científico publicado en 2012

Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome

artículo científico publicado en 2001

K1 protein of human herpesvirus 8 suppresses lymphoma cell Fas-mediated apoptosis

artículo científico publicado en 2006

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

artículo científico publicado en 2012

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

scientific article published on 03 April 2019

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

scientific article published on 15 September 2020

Long term results of a phase 2 study of vincristine sulfate liposome injection (Marqibo(®) ) substituted for non-liposomal vincristine in cyclophosphamide, doxorubicin, vincristine, prednisone with or without rituximab for patients with untreated ag

artículo científico publicado en 2013

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

artículo científico publicado en 2017

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

scientific article published on 02 September 2018

Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma

scientific article published on 28 February 2019

Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma.

artículo científico publicado en 2003

Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials

artículo científico publicado en 2020

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

artículo científico publicado en 2016

Mantle Cell International Prognostic Index (MIPI) not prognostic after R-hyper-CVAD.

artículo científico publicado en 2008

Mantle cell lymphoma with a rare involvement of the testicle

artículo científico publicado en 2007

Marginal zone lymphomas: factors that affect the final outcome

artículo científico publicado en 2010

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

artículo científico publicado en 2016

Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT.

artículo científico publicado en 2008

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

artículo científico publicado en 2010

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

scientific article published on 01 June 2019

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

artículo científico publicado en 2017

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

artículo científico publicado en 2016

Non-Hodgkin's Lymphomas, version 3.2012

artículo científico publicado en 2012

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology

artículo científico publicado en 2006

Non-Hodgkin's lymphomas

artículo científico publicado en 2008

Non-Hodgkin's lymphomas

artículo científico publicado en 2011

Non-Hodgkin's lymphomas, version 1.2013.

artículo científico publicado en 2013

Non-Hodgkin's lymphomas, version 2.2014

artículo científico publicado en 2014

Non-Hodgkin's lymphomas, version 4.2014.

artículo científico publicado en 2014

Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma

artículo científico publicado en 2003

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

artículo científico publicado en 2004

Novel treatment strategies for aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2006

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma

artículo científico publicado en 2013

Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

artículo científico publicado en 2018

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma.

artículo científico publicado en 2013

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

artículo científico publicado en 2012

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

artículo científico publicado en 2013

PET/CT with 18F-FLT is unlikely to cause significant hepatorenal or hematologic toxicity

artículo científico publicado en 2010

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

scientific article published on 08 July 2014

Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.

artículo científico publicado en 2016

Pegfilgrastim administered in a single fixed dose is effective in inducing neutrophil count recovery after paclitaxel and topotecan chemotherapy in patients with relapsed aggressive non-Hodgkin's lymphoma

artículo científico publicado en 2006

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Pentostatin in T-non-Hodgkin's lymphomas: efficacy and effect on CD26+ T lymphocytes

artículo científico publicado en 2003

Pentostatin, cyclophosphamide and rituximab for previously untreated advanced stage, low-grade B-cell lymphomas.

artículo científico publicado en 2015

Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity

scientific article published on 01 September 1999

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma

artículo científico publicado en 2008

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

artículo científico publicado en 2012

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

artículo científico publicado en 2008

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

artículo científico publicado en 2012

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

scientific article published on 26 April 2011

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

artículo científico publicado en 2013

Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2013

Phase I trial of bortezomib in combination with rituximab‐HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma ⬇️

artículo científico publicado el 5 de agosto de 2010

Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma

artículo científico publicado en 2017

Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

artículo científico publicado en 2008

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2015

Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms

artículo científico publicado en 2009

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

artículo científico publicado en 2015

Phase II study of denileukin diftitox for relapsed/refractory B-Cell non-Hodgkin's lymphoma

artículo científico publicado en 2004

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

artículo científico publicado en 2004

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

artículo científico publicado en 2004

Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma

artículo científico publicado en 2007

Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma

artículo científico publicado en 2007

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

artículo científico publicado en 2017

Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort

scientific article published on 16 June 2011

Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation

scientific article published on 07 April 2014

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

artículo científico publicado en 2019

Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy

artículo científico publicado en 2018

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma

artículo científico publicado en 2015

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

artículo científico publicado en 2015

Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma.

artículo científico publicado en 2007

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

artículo científico publicado en 2020

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma

scientific article published on 01 May 2019

Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>

artículo científico publicado en 2018

Prognostic factor analysis in mycosis fungoides/Sézary syndrome

artículo científico publicado en 1999

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

artículo científico publicado en 2016

Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma

artículo científico publicado en 2011

Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas.

artículo científico publicado en 2011

Prospective isolation of clonogenic mantle cell lymphoma-initiating cells

artículo científico publicado en 2010

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma.

artículo científico publicado en 2009

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

artículo científico publicado en 2018

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

artículo científico publicado en 2017

Radiotherapy alone for lymphocyte-predominant Hodgkin's disease

artículo científico publicado en 2002

Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

artículo científico publicado en 2015

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma

artículo científico publicado en 2016

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

artículo científico publicado en 2017

Rates of Positive Findings on Positron Emission Tomography and Bone Marrow Biopsy in Patients With Ocular Adnexal Lymphoma

artículo científico publicado en 2016

Recent advances in de novo CD5+ diffuse large B cell lymphoma

artículo científico

Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen

scientific article published on 01 May 2005

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy

artículo científico publicado en 2018

Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center

artículo científico publicado en 2015

Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience

scientific article published on 04 July 2019

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

scholarly article by Matthew J Reilley et al published 16 November 2018 in Journal for Immunotherapy of Cancer

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

artículo científico publicado en 2020

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

artículo científico publicado en 2013

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab

artículo científico publicado en 2013

Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.

artículo científico publicado en 2006

Safety of CAR T-cell therapy in patients with B-cell lymphoma and chronic hepatitis B or C virus infection

artículo científico publicado en 2019

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study

artículo científico publicado en 2010

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

artículo científico publicado en 2010

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography

artículo científico publicado en 2015

Sonic hedgehog signaling proteins and ATP-binding cassette G2 are aberrantly expressed in diffuse large B-cell lymphoma.

artículo científico publicado en 2009

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

artículo científico publicado en 2018

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

scientific article published on 08 January 2019

Stage III follicular lymphoma: long-term follow-up and patterns of failure.

artículo científico publicado en 2003

Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins

artículo científico publicado en 2013

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

artículo científico publicado en 2012

Targeting Wnt pathway in mantle cell lymphoma-initiating cells.

artículo científico publicado en 2015

Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma

artículo científico publicado en 2010

The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study

artículo científico publicado en 2016

The absolute monocyte and lymphocyte prognostic index for patients with diffuse large B-cell lymphoma who receive R-CHOP

artículo científico publicado en 2012

The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma

artículo científico publicado en 2007

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

artículo científico publicado en 2014

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.

artículo científico publicado en 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2016

Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia

artículo científico publicado en 2001

Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis

artículo científico publicado en 1998

Treating Rosai-Dorfman disease and RAS-associated autoimmune leucoproliferative disorder with malignant transformation

artículo científico publicado en 2020

Treatment of the patient with diffuse large B-cell lymphoma with medical co-morbidities: newer therapies needed

scientific article published on 01 April 2007

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2019

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

artículo científico publicado en 2007

Updated Results of Rituximab Pre- and Post-BEAM with or without 90Yttrium Ibritumomab Tiuxetan during Autologous Transplant for Diffuse Large B-cell Lymphoma.

artículo científico publicado en 2018

Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production

artículo científico publicado en 2012

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial

artículo científico publicado en 2012

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda